Market Introduction
Enzymes are proteins produced in living cells of plants, animals, and microorganisms. All living organisms require enzymes for growth and for the production and utilization of energy which is essential for life. In the living cell, enzymes act as catalysts to speed up the chemical reactions which control life processes. Enzymes have been significant industrial products for more than a hundred years. However, the range of potential applications is increasing rapidly. With the advent of recombinant DNA technology, it has become possible to make formerly rare enzymes in large quantities and hence to reduce cost. Also, in pharmaceutical manufacturing, the desire to make chirally pure compounds is leading to new opportunities. Technological advances have facilitated the use of enzymes over an increasingly broad range of process conditions.
Thus, the significant increase in research and development activities is expected to create a significant demand for medical enzyme technology in the coming years, which is further anticipated to drive the medical enzyme technology market.
COVID-19 cases are increasing in South and Central America. With the outbreak of the second wave of COVID-19, the number of cases in Latin American countries has increased. Now, the nation is increasingly expanding its clinical services to combat the novel corona virus. Despite this impact, the region's biotechnology industry is doing little to fight the virus, and the lack of projects has exposed the sector's vulnerability. There are a few unrelated and autonomous projects going on, but they are happening independently of one another, meaning that there is no strong biotech network. Just a smattering of the hundreds of COVID-19 vaccine or drug projects ongoing worldwide are in a region of over 652 million inhabitants and a slew of middle-income countries. Just six independent biotech projects in Latin America are currently addressing COVID-19, either in search of a vaccine or a cure for the novel coronavirus. None of them are about to undergo clinical trials.
Market Overview and Dynamics
The Medical enzyme technology market in South and Central America is expected to grow from US$ 279.3 million in 2021 to US$ 412.1 million by 2028; it is estimated to grow at a CAGR of 5.7% from 2021 to 2028. Biopharmaceuticals are among the growing business segments of the pharmaceutical and biotechnology industries. Since their introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases, and they are increasingly used in nearly all medicine branches. Despite the immense time and financial effort required, the market of biopharmaceuticals is rapidly growing.
Key Market Segments
In terms of enzyme type, the hydrolases segment accounted for the largest share of the South and Central America medical enzyme technology market in 2020. In terms of application, the disease treatment segment accounted for the largest share of the South and Central America medical enzyme technology market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the medical enzyme technology market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck Kgaa, Thermo Fisher Scientific Inc., Novozymes, Takeda Pharmaceutical Company Limited, Agilent Technologies, Inc., Genzyme Corporation, Asahi Kasei Corporation, Promega Corporation, Cytiva, and Amano Enzyme Inc.
Reasons to buy report
SOUTH AND CENTRAL AMERICA MEDICAL ENZYME TECHNOLOGY MARKET SEGMENTATION
By Enzyme Type
By Application
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 279.3 Million |
| Market Size by 2028 | US$ 412.1 Million |
| CAGR (2021 - 2028) | 5.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Enzyme Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South and Central America Medical Enzyme Technology Market is valued at US$ 279.3 Million in 2021, it is projected to reach US$ 412.1 Million by 2028.
As per our report South and Central America Medical Enzyme Technology Market, the market size is valued at US$ 279.3 Million in 2021, projecting it to reach US$ 412.1 Million by 2028. This translates to a CAGR of approximately 5.7% during the forecast period.
The South and Central America Medical Enzyme Technology Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Medical Enzyme Technology Market report:
The South and Central America Medical Enzyme Technology Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Medical Enzyme Technology Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Medical Enzyme Technology Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Medical Enzyme Technology Market
